<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195633</url>
  </required_header>
  <id_info>
    <org_study_id>RG1005742</org_study_id>
    <secondary_id>NCI-2019-07697</secondary_id>
    <secondary_id>10343</secondary_id>
    <nct_id>NCT04195633</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies</brief_title>
  <official_title>Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well a donor stem cell transplant, treosulfan, fludarabine,&#xD;
      and total-body irradiation work in treating patients with blood cancers (hematological&#xD;
      malignancies). Giving chemotherapy and total-body irradiation before a donor stem cell&#xD;
      transplant helps stop the growth of cells in the bone marrow, including normal blood-forming&#xD;
      cells (stem cells) and cancer cells. It may also stop the patient's immune system from&#xD;
      rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into&#xD;
      the patient, they may help the patient's bone marrow make stem cells, red blood cells, white&#xD;
      blood cells, and platelets. The donated stem cells may also replace the patient's immune&#xD;
      cells and help destroy any remaining cancer cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: Patients are assigned to 1 of 2 arms.&#xD;
&#xD;
      ARM A (HIGH DOSE TREOSULFAN): Patients receive high dose treosulfan intravenously (IV) over&#xD;
      120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients&#xD;
      then undergo total-body irradiation on day -1 and allogeneic hematopoietic stem cell&#xD;
      transplantation on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days&#xD;
      3-4. Beginning on day 5, patients receive cyclosporine IV twice daily (BID) or three times&#xD;
      daily (TID) over 1-2 hours or orally (PO) (after 3 months, in the absence of GVHD,&#xD;
      cyclosporine tapering will start by 5-10% per week, until drug withdrawal at 6 months&#xD;
      post-transplant). Beginning on day 5, patients also receive mycophenolate sodium PO TID or&#xD;
      mycophenolate mofetil IV or PO TID until day 35 (may be continued if active GVHD is present).&#xD;
      Beginning on day 5, patients also receive filgrastim until the absolute neutrophil count is &gt;&#xD;
      1,000/uL for 3 consecutive days.&#xD;
&#xD;
      ARM B (LOW DOSE TREOSULFAN): Patients receive low dose treosulfan IV over 120 minutes on days&#xD;
      -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo&#xD;
      total-body irradiation and allogeneic hematopoietic stem cell transplantation, and receive&#xD;
      cyclophosphamide, cyclosporine, mycophenolate sodium or mycophenolate mofetil, and filgrastim&#xD;
      as in Arm A.&#xD;
&#xD;
      After completion of transplant, patients are followed up at 28, 56, 84, 365, and 730 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 25, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Graft failure/rejection</measure>
    <time_frame>Up to 2 years post-transplant</time_frame>
    <description>The analysis for graft failure will be conducted among all patients as well as separately among patients by Arm A versus Arm B.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 1- and 2-years post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>At 1 year post-transplant</time_frame>
    <description>Defined as the probability of being alive without sign of disease relapse or progression. Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-relapse mortality</measure>
    <time_frame>At day 100 and 1 year post-transplant</time_frame>
    <description>Defined as death from any cause without sign of disease progression or relapse. Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of relapse</measure>
    <time_frame>At 1- and 2-years post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute graft versus host disease</measure>
    <time_frame>Up to 2 years post-transplant</time_frame>
    <description>Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic graft versus host disease</measure>
    <time_frame>Up to 2 years post-transplant</time_frame>
    <description>Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant infections</measure>
    <time_frame>Up to 2 years post-transplant</time_frame>
    <description>Clinically significant infections include infections that have a significant impact on patient's clinical recovery, for instance infections that require in-patient hospitalization or prolongs existing hospitalization. Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet engraftment</measure>
    <time_frame>At day 100 post-transplant</time_frame>
    <description>Defined as the first of three consecutive days with platelet count &gt;= 20,000/uL on the peripheral blood, without platelet transfusion in the previous seven days. Will be summarized using Kaplan-Meier and cumulative incidence estimates, as appropriate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Acute Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Adult Diffuse Large Cell Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <condition>Burkitt Lymphoma</condition>
  <condition>Chronic Myelogenous Leukemia, BCR-ABL1 Positive</condition>
  <condition>Chronic Myelomonocytic Leukemia</condition>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Lymphoblastic Lymphoma</condition>
  <condition>Lymphoplasmacytic Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Mixed Phenotype Acute Leukemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Prolymphocytic Leukemia</condition>
  <condition>Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Refractory Follicular Lymphoma</condition>
  <condition>Refractory Marginal Zone Lymphoma</condition>
  <condition>Refractory Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A (high dose treosulfan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive high dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation on day -1 and allogeneic hematopoietic stem cell transplantation on day 0. Patients then receive cyclophosphamide IV over 1-2 hours on days 3-4. Beginning on day 5, patients receive cyclosporine IV BID or TID over 1-2 hours or PO (after 3 months, in the absence of GVHD, cyclosporine tapering will start by 5-10% per week, until drug withdrawal at 6 months post-transplant). Beginning on day 5, patients also receive mycophenolate sodium PO TID or mycophenolate mofetil IV or PO TID until day 35 (may be continued if active GVHD is present). Beginning on day 5, patients also receive filgrastim until the absolute neutrophil count is &gt; 1,000/uL for 3 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (low dose treosulfan)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive low dose treosulfan IV over 120 minutes on days -6 to -4 and fludarabine IV over 60 minutes on days -6 to -2. Patients then undergo total-body irradiation and allogeneic hematopoietic stem cell transplantation, and receive cyclophosphamide, cyclosporine, mycophenolate sodium or mycophenolate mofetil, and filgrastim as in Arm A.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo allogeneic hematopoietic stem cell transplantation</description>
    <arm_group_label>Arm A (high dose treosulfan)</arm_group_label>
    <arm_group_label>Arm B (low dose treosulfan)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplantation, Allogeneic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (high dose treosulfan)</arm_group_label>
    <arm_group_label>Arm B (low dose treosulfan)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm A (high dose treosulfan)</arm_group_label>
    <arm_group_label>Arm B (low dose treosulfan)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Cyclosporine Modified</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (high dose treosulfan)</arm_group_label>
    <arm_group_label>Arm B (low dose treosulfan)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tevagrastim</other_name>
    <other_name>Filgrastim-aafi</other_name>
    <other_name>Nivestym</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (high dose treosulfan)</arm_group_label>
    <arm_group_label>Arm B (low dose treosulfan)</arm_group_label>
    <other_name>Fluradosa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Arm A (high dose treosulfan)</arm_group_label>
    <arm_group_label>Arm B (low dose treosulfan)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Sodium</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Arm A (high dose treosulfan)</arm_group_label>
    <arm_group_label>Arm B (low dose treosulfan)</arm_group_label>
    <other_name>ERL 080</other_name>
    <other_name>ERL 080A</other_name>
    <other_name>Socium Mycophenolate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo total-body irradiation</description>
    <arm_group_label>Arm A (high dose treosulfan)</arm_group_label>
    <arm_group_label>Arm B (low dose treosulfan)</arm_group_label>
    <other_name>TBI</other_name>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
    <other_name>SCT_TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm A (high dose treosulfan)</arm_group_label>
    <arm_group_label>Arm B (low dose treosulfan)</arm_group_label>
    <other_name>1,2,3, 4-Butanetetrol, 1,4-dimethanesulfonate, [R-(R*,S*)]-</other_name>
    <other_name>Dihydroxybusulfan</other_name>
    <other_name>Ovastat</other_name>
    <other_name>Treosulphan</other_name>
    <other_name>Tresulfon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute leukemia (AL) that includes acute myeloid leukemia (AML) / acute lymphoblastic&#xD;
             leukemia (ALL) / mixed phenotype leukemia (MPAL) in complete morphological remission&#xD;
             (CR) with or without detectable minimal residual disease (MRD); complete morphological&#xD;
             remission is defined by the presence of less than 5% of detectable blasts in bone&#xD;
             marrow specimen, evaluated no earlier than one month before conditioning regimen&#xD;
             start. Patients with documented CR but without hematologic recovery since last&#xD;
             chemotherapy are considered eligible to the study&#xD;
&#xD;
          -  Chronic myelogenous leukemia (CML), except refractory blast crisis. To be eligible in&#xD;
             first chronic phase, patients must have failed or be intolerant to at least one&#xD;
             tyrosine-kinase inhibitor&#xD;
&#xD;
          -  Chronic myelomonocytic leukemia (CMML)&#xD;
&#xD;
          -  Myelodysplastic syndromes (MDS)&#xD;
&#xD;
          -  Lymphoblastic, Burkitt's and other high-grade lymphoma in any complete (CR) or partial&#xD;
             (PR) response&#xD;
&#xD;
               -  CR and PR are defined according to Lugano classification: Recommendations for&#xD;
                  Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin&#xD;
                  Lymphoma: The Lugano Classification&#xD;
&#xD;
          -  Low grade lymphoma (chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma&#xD;
             [SLL], marginal zone lymphoma, follicular lymphoma) progressed after two treatment&#xD;
             regimens, in CR/PR&#xD;
&#xD;
               -  For CLL/SLL, CR and PR are defined according to: International Workshop on CLL&#xD;
                  (iwCLL) guidelines for diagnosis, indications for treatment, response assessment,&#xD;
                  and supportive management of CLL&#xD;
&#xD;
               -  CR and PR are defined according to Lugano classification: Recommendations for&#xD;
                  Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin&#xD;
                  Lymphoma: The Lugano Classification&#xD;
&#xD;
          -  Large cell lymphoma in &gt; second CR (CR2)/ &gt;= PR2&#xD;
&#xD;
               -  CR and PR are defined according to Lugano classification: Recommendations for&#xD;
                  Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin&#xD;
                  Lymphoma: The Lugano Classification&#xD;
&#xD;
          -  Mantle cell lymphoma, lymphoplasmacytic lymphoma and prolymphocytic leukemia may be&#xD;
             eligible after initial therapy if in CR/PR&#xD;
&#xD;
               -  CR and PR are defined according to Lugano classification: Recommendations for&#xD;
                  Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin&#xD;
                  Lymphoma: The Lugano Classification&#xD;
&#xD;
               -  For prolymphocytic leukemia (PLL), CR is defined as a normalization of&#xD;
                  lymphadenopathies (long-axis diameter &lt; 1 cm) and splenomegaly (&lt; 13 cm), absence&#xD;
                  of constitutional symptoms, PLL cells &lt; 5% in bone marrow and circulating&#xD;
                  lymphocytes count &lt; 4 x 10^9/L. Patients without hematopoietic recovery are&#xD;
                  considered eligible to the study. PR is defined as a decrease of &gt;= 30% of the&#xD;
                  sum of lymphadenopathies' long-axis diameters, a decrease of &gt;= 50% in spleen&#xD;
                  vertical length beyond normal from baseline, peripheral blood (PB) lymphocytes =&lt;&#xD;
                  30 x 10^9/L (and a decrease of &gt;= 50% from baseline)&#xD;
&#xD;
          -  Hodgkin Lymphoma in &gt; CR2/PR2&#xD;
&#xD;
               -  CR and PR are defined according to Lugano classification: Recommendations for&#xD;
                  Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin&#xD;
                  Lymphoma: The Lugano Classification&#xD;
&#xD;
          -  Subjects must be &gt;= 6 months old&#xD;
&#xD;
          -  Karnofsky &gt;= 70 or Eastern Cooperative Oncology Group (ECOG) 0-1 (for adults)&#xD;
&#xD;
          -  Lansky score &gt;= 50 (for children)&#xD;
&#xD;
          -  Adequate cardiac function defined as absence of decompensated congestive heart failure&#xD;
             or uncontrolled arrhythmia AND left ventricular ejection fraction &gt;= 40% or shortening&#xD;
             fraction &gt; 22%&#xD;
&#xD;
          -  Adequate pulmonary function defined as absence of oxygen (O2) requirements and one of&#xD;
             the following:&#xD;
&#xD;
               -  Diffusion capacity of the lung for carbon monoxide (DLCO) corrected &gt;= 70% mm Hg&#xD;
&#xD;
               -  DLCO corrected between 60% - 69% mm Hg and partial pressure of oxygen (pO2) &gt;= 70&#xD;
                  mm Hg&#xD;
&#xD;
               -  DLCO corrected between 50% - 59% mm Hg and pO2 &gt;= 80 mm Hg Pediatric patients&#xD;
                  unable to perform pulmonary function tests must have O2 saturation &gt;= 92% on room&#xD;
                  air. May not be on supplemental oxygen&#xD;
&#xD;
          -  Total bilirubin &lt; 2 x upper limit of normal (ULN) unless felt to be related to&#xD;
             Gilbert's disease or hemolysis&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 2.5 x ULN&#xD;
&#xD;
          -  Alkaline phosphatase =&lt; 5 x ULN&#xD;
&#xD;
          -  Creatinine &lt; 2.0 mg/dl (adults) or estimated creatinine clearance &gt; 40 ml/min&#xD;
             (pediatrics)&#xD;
&#xD;
               -  All adults with a creatinine &gt; 1.2 or a history of renal dysfunction must have&#xD;
                  estimated creatinine clearance &gt; 40 ml/min&#xD;
&#xD;
          -  If recent mold infection, e.g., aspergillus, must be cleared by infectious disease to&#xD;
             proceed&#xD;
&#xD;
          -  Patients who have undergone prior allogeneic hematopoietic cell transplant are&#xD;
             eligible, but the prior transplant must have been performed at least 3 months prior to&#xD;
             enrollment, unless in case of graft failure from the prior transplant&#xD;
&#xD;
          -  Written and signed informed consent&#xD;
&#xD;
          -  DONOR: Donors must be haploidentical relatives of the patients. Donor-recipient&#xD;
             compatibility will be tested through HLA typing at high resolution for the HLA loci&#xD;
             (-A, -B, -C, -DRB1, -DQB1). Donor and recipient should share at least 5/10 HLA loci&#xD;
&#xD;
          -  DONOR: Age &gt;= 12 years&#xD;
&#xD;
          -  DONOR: Weight &gt;= 40 Kg&#xD;
&#xD;
          -  DONOR: Ability of donors younger than 18 years of age to undergo apheresis without use&#xD;
             of a vascular access device. Vein check must be performed and verified by an apheresis&#xD;
             nurse prior to arrival at the Seattle Cancer Care Alliance (SCCA)&#xD;
&#xD;
          -  DONOR: Donor must meet selection criteria as defined by the Foundation of the&#xD;
             Accreditation of Cell Therapy (FACT) and will be screened per the American Association&#xD;
             of Blood Banks (AABB) guidelines&#xD;
&#xD;
          -  DONOR: In case of more available haploidentical donors, selection criteria should&#xD;
             include, in this order:&#xD;
&#xD;
               -  For cytomegalovirus (CMV) seronegative recipients, a CMV seronegative donor&#xD;
&#xD;
               -  Red blood cell compatibility&#xD;
&#xD;
                    -  Red blood cell (RBC) cross match compatible&#xD;
&#xD;
                    -  Minor ABO incompatibility&#xD;
&#xD;
                    -  Major ABO incompatibility&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active, uncontrolled, life-threatening viral, bacterial or fungal infection requiring&#xD;
             treatment at time of conditioning regiment administration and transplantation&#xD;
&#xD;
          -  Presence of a malignancy other than the one for which the transplant is being&#xD;
             performed, with an expected survival less than 75% at 5 years&#xD;
&#xD;
          -  Pregnant or breastfeeding&#xD;
&#xD;
          -  Known hypersensitivity to treosulfan, fludarabine or cyclophosphamide&#xD;
&#xD;
          -  Dosing with another investigational agent within 30 days prior to entry in the study&#xD;
&#xD;
          -  Central nervous system (CNS) leukemic involvement not clearing with intrathecal&#xD;
             chemotherapy and/or cranial radiation prior to initiation of conditioning (day -6)&#xD;
&#xD;
          -  DONOR: Since detection of anti-donor-specific-antigen antibodies (anti-DSA) is&#xD;
             associated with higher graft rejection rate, patients will be screened for anti-DSA&#xD;
             pre-transplant. Patients with DSA will be reviewed by the principal investigator and&#xD;
             considered for desensitization treatment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo Milano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Filippo Milano</last_name>
    <phone>206.667.5925</phone>
    <email>fmilano@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Filippo Milano</last_name>
      <phone>206-667-5925</phone>
      <email>fmilano@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Filippo Milano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Burkitt Lymphoma</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
    <mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

